Menu
Back to Journals » Blood and Lymphatic Cancer: Targets and Therapy » Volume 2
Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future
Authors Sinha, Nastoupil, Flowers C
Received 1 October 2011
Accepted for publication 25 October 2011
Published 19 April 2012 Volume 2012:2 Pages 87—98
DOI https://doi.org/10.2147/BLCTT.S18701
Review by Single anonymous peer review
Peer reviewer comments 2
Rajni Sinha1, Loretta J Nastoupil2, Christopher R Flowers1
1Department of Hematology/Medical Oncology, Winship Cancer Institute, 2Department of Hematology and Oncology, Emory University, Atlanta, GA, USA
Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring lymphoma in the Western world. DLBCLs are clinically, biologically, and pathologically heterogeneous with biologically distinct subtypes that have different expected treatment outcomes. The addition of rituximab to combination chemotherapy has improved outcomes for all patients with DLBCL and can cure the disease in certain individuals. Relapsed DLBCL is generally managed with salvage chemoimmunotherapy followed by high-dose therapy and autologous stem cell transplantation, which can cure additional patients. However, outcomes for patients who relapse early after upfront rituximab and chemotherapy are poor. Novel therapies and strategies are desperately needed for these patients and several emerging treatments hold promise for improving DLBCL treatment outcomes.
Keywords: non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, lymphoma, chemoimmunotherapy, rituximab, treatment
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.